Metformin 1,700 mg/day and Dapagliflozin 10 mg/day for a year.

PreDiabetes

Obesity, Morbid

Diabetes Mellitus, Type 2

Two tablets of Metformin 850 mg every 12 hours will be provided in combination with Dapagliflozin 10 mg per day. Each participant will receive diet and exercise intervention according to their BMI and current physical condition.

Dapagliflozin/Metformin

Two tablets of Metformin 850 mg every 12 hours will be provided. Each participant will receive diet and exercise intervention according to their BMI and current physical condition.

Metformin

Hospital de Especialidades Centro Médico Nacional Siglo XXI

Effectiveness of Dapagliflozin for Weight Loss

Effectiveness of the Treatment With Dapagliflozin and Metformin Compared to Metformin Monotherapy for Weight Loss on Diabetic and Prediabetic Patients With Obesity Class III

Change of 10 percent of initial blood pressure (systolic and diastolic)

Change of 10 percent of initial waist circumference

Change of 10 percent of initial triglycerides levels

Change in interleukin-6, interleukin-10, adiponectin, and resistin, comparing initial versus final levels

Aldo Ferreira Hermosillo

Research Associate

Centro Medico Nacional Siglo XXI IMSS

Randomized single-blind controlled clinical trial

Patients will be randomised to switch from a boosted PI to dolutegravir at baseline.

Patients will be randomised to switch from a boosted PI to dolutegravir after 48 weeks.

Dolutegravir

Insititute Of Tropical Medicine Antwerp

CHU Saint-Pierre

Universitaire Ziekenhuis Gent

Hopital de la Croix Rousse

Service des Maladies Infectieuses et Tropicales du CHU de NANTES

Hopital Saint Louis

Pitié-Salpêtrière Hospital

Hospital Bichat Claude-Bernard

Universitätsklinikum Bonn

Universitätsklinikum Essen

Klinikum der Goethe-Universität Frankfurt

ICH Infektiologisches Centrum Hamburg

Medizinische Hochschule Hannover

Santa Maria Annunziata di Firenze

San Paolo Hospital

Azienda Ospedaliera - Polo Universitario 'Luigi Sacco'

Universitaria di Modena

Universitario Alicante

Hospital General Universitario de Elche

Hospital de la Santa Creu i Sant Pau

Hospital Clinic Barcelona

Universitari de Bellvitge

IrsiCaixa

Hospital Ramon y Cajal

Hospital Universitario La Paz

Elton John Centre

Southmead Hospital

Bart's Hospital

Royal Free Hospital

St Thomas Hospital

Chelsea & Westminster Hospital

St Mary's Hospital

Mortimer Market Centre

Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG)

An Open Label Study Examining the Efficacy and Cardiovascular Risk of Immediate Versus Deferred Switch From a Boosted PI to Dolutegravir (DTG) in HIV Infected Patients With Stable Virological Suppression

Maintenance of virological suppression (ie HIV-1 RNA <50 c/ml) after 48 weeks

Change from baseline in total cholesterol at week 48

Maintenance of virological suppression (ie HIV-1 RNA <50 c/ml) at week 24 and 96

Change in CD4 count from baseline to week 24, 48 and 96

Change from baseline in total cholesterol at weeks 24 and 96

Change from baseline to lipid values (LDL, HDL, triglycerides and TC:HDL ratio) and Framingham and DAD scores at weeks 24, 48 and 96

Safety (clinical and laboratory adverse events) at weeks 24, 48 and 96

Changes in markers of inflammation at baseline, week 48 and week 96

Tolerability (EuroQoL questionnaire) at weeks 24, 48 and 96

Changes in markers of coagulation at baseline, week 48 and week 96

Changes in markers of endothelial dysfunction at baseline, week 48 and week 96

Change from baseline to arterial stiffness augmentation index at weeks 48 and 96

Change from baseline to average thickness of common carotid artery walls at weeks 48 and 96

St Stephens Aids Trust

Type 1 Diabetes

Pramlintide will be started at 15 mcg (2.5 units) subcutaneously immediately prior to major meals and it will be increased by 15mcg every 3 days as tolerated (i.e. nausea, vomiting, upset stomach) to a maximum dose of 60 mcg (10 units) before meals. If significant nausea persists at 45 or 60 mcg level, the dose should be decreased to 30 mcg (5 units) before meals. If the 30 mcg dose is not tolerated, investigator will evaluate for possibility of withdrawing the pramlintide. The dose of preprandial short acting insulin (eg: Novolog/Humalog) will be reduced by 30 to 50% at the start of pramlintide 15 mcg (2.5 units) and then will be adjusted every time the dose of pramlintide is increased by 15 mcg (2.5 units) as needed based on blood glucose readings.

glycosuria/triglyceride

Effectiveness of Dapagliflozin for Weight Loss

Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG)

Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes

قاعدة بيانات الأعشاب الطبية الأكثر اكتمالا التي يدعمها العلم